The prognostic significance of IDH2 mutations in AML depends on the location of the mutation
Autor: | Rosemary E. Gale, Lu Zhao, Robert Kerrin Hills, Alan Kenneth Burnett, David C. Linch, Claire Green, Catherine M Evans |
---|---|
Rok vydání: | 2011 |
Předmět: |
Adult
Male Oncology medicine.medical_specialty NPM1 Genotype DNA Mutational Analysis Immunology Biology Enasidenib medicine.disease_cause Biochemistry IDH2 Cohort Studies Recurrence Internal medicine Biomarkers Tumor medicine Humans Survival analysis Mutation Base Sequence Case-control study Cytogenetics Cell Biology Hematology Middle Aged Prognosis Survival Analysis Isocitrate Dehydrogenase Leukemia Myeloid Acute Case-Control Studies Cancer research Female Nucleophosmin |
Zdroj: | Blood. 118:409-412 |
ISSN: | 1528-0020 0006-4971 |
Popis: | We have investigated the prognostic significance of isocitrate dehydrogenase 2 (IDH2) mutations in 1473 younger adult acute myeloid leukemia patients treated in 2 United Kingdom Medical Research Council trials. An IDH2 mutation was present in 148 cases (10%), 80% at R140 and 20% at R172. Patient characteristics and outcome differed markedly between the 2 mutations. IDH2R140 significantly correlated with nucleophosmin mutations (NPM1MUT), whereas IDH2R172 cases generally lacked other molecular mutations. An IDH2R140 mutation was an independent favorable prognostic factor for relapse (P = .004) and overall survival (P = .008), and there was no significant heterogeneity with regard to NPM1 or FLT3 internal tandem duplication (FLT3/ITD) genotype. Relapse in FLT3/ITDWTNPM1MUTIDH2R140 patients was lower than in favorable-risk cytogenetics patients in the same cohort (20% and 38% at 5 years, respectively). The presence of an IDH2R172 mutation was associated with a significantly worse outcome than IDH2R140, and relapse in FLT3/ITDWTNPM1WTIDH2R172 patients was comparable with adverse-risk cytogenetics patients (76% and 72%, respectively). |
Databáze: | OpenAIRE |
Externí odkaz: |